Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 96.5% in August

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the recipient of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 1,646,299 shares, a growth of 96.5% from the July 30th total of 837,868 shares. Based on an average daily trading volume, of 33,615,368 shares, the short-interest ratio is presently 0.0 days. Approximately 7.6% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Valion Bio, Inc. Common Stock Stock Up 20.8%

NASDAQ VBIO traded up $0.63 during trading hours on Monday, hitting $3.65. The company had a trading volume of 361,932 shares, compared to its average volume of 143,954. The firm’s 50 day moving average is $0.35 and its 200 day moving average is $0.70. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.86. Valion Bio, Inc. Common Stock has a fifty-two week low of $2.79 and a fifty-two week high of $80.19. The company has a market capitalization of $80.99 million, a price-to-earnings ratio of -0.57 and a beta of 1.85.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.17) EPS for the quarter, topping analysts’ consensus estimates of ($408.00) by $405.83.

Hedge Funds Weigh In On Valion Bio, Inc. Common Stock

An institutional investor recently bought a new stake in Valion Bio, Inc. Common Stock stock. Foster & Motley Inc. acquired a new stake in shares of Valion Bio, Inc. Common Stock (NASDAQ:VBIO) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 53,728 shares of the company’s stock, valued at approximately $2,715,000. Foster & Motley Inc. owned 1.29% of Valion Bio, Inc. Common Stock as of its most recent SEC filing. 4.25% of the stock is owned by institutional investors and hedge funds.

Valion Bio, Inc. Common Stock Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.